The company said total revenues for Q1 2025 were $3,029 million, down 4% from $3,145 million a year earlier. GAAP diluted earnings per share were $7.27 (versus $6.27 a year earlier), and non-GAAP diluted earnings per share were $8.22 (versus $9.55 a year earlier).

1. 01

   The company said total revenues for Q1 2025 were $3,029 million, down 4% from $3,145 million a year earlier. GAAP diluted earnings per share were $7.27 (versus $6.27 a year earlier), and non-GAAP diluted earnings per share were $8.22 (versus $9.55 a year earlier).

2. 02

   Regeneron said EYLEA HD U.S. net sales for Q1 2025 rose 54% from a year earlier to $307 million, while combined U.S. net sales of EYLEA HD and EYLEA fell 26% to $1.04 billion. It said Dupixent global net sales recorded by Sanofi rose 19% to $3.67 billion.

3. 03

   The company said it adjusted its 2025 full-year outlook for GAAP gross margin on net product sales from 84% to 85% to 83% to 84%, and for non-GAAP from 87% to 88% to 86% to 87%. It adjusted capital expenditures from $850 to $975 million to $850 to $950 million.

Analysis scope · Filing body and confirmed press-release exhibitWe analyzed the filing body and confirmed exhibits. This is not a review of other exhibits, investor presentations or the full earnings call. Some paragraphs were omitted because their support in the source could not be confirmed.

AI summarized the filing and translated the summary into English; it may differ from the original. For reference only, not investment advice. AI translated the published Korean report into English. Figures are copied as filed, not recalculated.

Original filing

The filing as submitted to SEC EDGAR. You can check the figures and statements of this summary against it.